2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 391

Current Provider Practices and Perceived Barriers for Mental Health Care of Adolescents with SLE

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 3

Cytokine Production Patterns in Osteoporosis Suggest a Pro-Inflammatory Bias

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 731

Damage and Mortality in SLE: Cluster Analysis of Patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 876

Damage Develops Early and Is Common in Children with Chronic Systemic Vasculitis

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 70

Data from Brazilian Fibromyalgia Patients Registry (EPIFIBRO) in 2014

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

9:00AM-11:00AM: Abstract Number: 732

Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 502

Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 587

Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 132

Delivering a One-Stop, Integrated, Patient-Centred Service for Patients with Rheumatic Diseases. the Finnish Approach

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 12

Delta-like 1 Enhances the Production of Pro-Inflammatory Mediators By Fibroblast-like Synoviocytes

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 384

Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 747

Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 395

Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 420

Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 187

Detection of Power Doppler Ultrasound Signals in Rheumatic Diseases Using Superb Microvascular Imaging (SMI): Comparison with Conventional Power Doppler Ultrasound

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].